{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"116"}],"title":"Number of participants for whom a releasable CAR T cell product was manufactured"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"}],"title":"Number of participants for whom no releasable CAR T cell product was manufactured"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"119"}],"units":"Participants"}],"description":"The feasibility of manufacturing and releasing T cell products from pediatric and young adult patients with CD19+ relapsed or refractory leukemia","groups":[{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\\^5 CAR T cells/kg","id":"OG000","title":"Phase 1-Cohort 1A"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^6 CAR T cells/kg","id":"OG001","title":"Phase 1-Cohort 1B"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\\^6 CAR T cells/kg","id":"OG002","title":"Phase 1-Cohort 1C"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^7 CAR T cells/kg","id":"OG003","title":"Phase 1-Cohort 1D"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 5x10\\^5 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide","id":"OG004","title":"Phase 1-Cohort 1F1"},{"description":"This phase 1 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^6 CAR T cells/kg following prescribed lymphodepletion with fludarabine and cyclophosphamide","id":"OG005","title":"Phase 1-Cohort 1F2"},{"description":"This phase 1 cohort did not receive Patient Derived CD19 specific CAR T cells","id":"OG006","title":"Phase 1 - Not Treated"},{"description":"The phase 2 cohort received Patient Derived CD19 specific CAR T cells at a dose of 1x10\\^6 CAR T cells/kg following lymphodepletion if indicated","id":"OG007","title":"Phase 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants evaluable for manufacturing feasibility.","reportingStatus":"POSTED","timeFrame":"Up to 28 days per manufacturing attempt","title":"Number of Participants Who Have a Releasable Cell Product Generated","type":"PRIMARY","unitOfMeasure":"Participants"}